AC Immune
ACIU · Nasdaq · Switzerland
Share price · ACIU
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ACIU's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 1 Oct 2026+7.3%
Nothing announced by ACIU that day or the session before.
- 21 Aug 2026+9.8%
- 11 Aug 2026+11.4%
- 30 Jun 2026-10.5%
- 28 May 2026-6.1%
Nothing announced by ACIU that day or the session before.
- 28 Apr 2026+6.7%
Nothing announced by ACIU that day or the session before.
- 7 Apr 2026+15.2%
- 18 Feb 2026-10.0%
- Day beforeAC Immune: 6-K filing
- 11 Dec 2025+15.4%
Share of unusual movement by asset
For each asset, the share of ACIU's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 25% |
| Sessions with no dated event | — | 75% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | TauVaccine | Alzheimer's Disease | |
| Phase 2 | alpha-synucleinVaccine | Parkinson's Disease | |
| Phase 1/2 | Amyloid-betaVaccine | Alzheimer's Disease |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2028 (1)
June 2028 (1)
What to watch
2029 (1)
April 2029 (1)
What to watch
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $1.6M | $20M | $32M+ $128M short-term inv. | $26M | report ↗ |
AC Immune reported revenue of $1.59M for Q2 2025, up 109.2% YoY, with R&D spend of $20.39M, up 7.6% YoY. Cash and equivalents were $32.44M, and the company posted a net loss of $25.68M, equal to its quarterly net burn of $25.68M.
Management announced a strategic review leading to a workforce reduction of around 30% and extended cash resources, reported as CHF 127.1M as of June 30, 2025, expected to fund operations through the end of Q3 2027 excluding potential partnering payments. Guidance was maintained for previously announced timelines, with interim clinical data from ACI-7104.056 and ACI-24.060 expected in H2 2025 and H1 2026, respectively, while pipeline focus shifts to Phase 2 active immunotherapies and small molecule programs targeting NLRP3 and Tau.
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | $0.8M | $19M | $57M+ $137M short-term inv. | $25M | report ↗ |
| 2023-Q2 | $0 | $15M | $45M+ $59M short-term inv. | $19M | report ↗ |
| 2022-Q3 | $4.1M | $15M | $45M | $14M-$14M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $16M | $66M | $20M | report ↗ |
| 2021-Q3 | $0 | $16M | $100M | $17M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $4.3M | $68M | $34M+ $82M short-term inv. | $21M-$84M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $31M | $71M | $40M+ $143M short-term inv. | $14M$75M operating cash flow | report ↗ |
| 2023-FY | $16M | $61M | $93M+ $29M short-term inv. | $15M-$67M operating cash flow | report ↗ |
| 2022-FY | $4.1M | $63M | $34M+ $98M short-term inv. | $19M-$77M operating cash flow | report ↗ |
| 2021-FY | $0 | $68M | $90M+ $127M short-term inv. | $20M-$72M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($31K), 2 sales ($59K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-11 | June Carl Howard · director | Award / grant | 16,568 | — | — | Form 4 |
| 2026-06-11 | Buetler Monika · director | Award / grant | 17,751 | — | — | Form 4 |
| 2026-06-11 | Zuegel Martin · director, Interim CEO | Award / grant | 33,136 | — | — | Form 4 |
| 2026-06-11 | AGUIAR-LUCANDER RENEE · director | Award / grant | 16,568 | — | — | Form 4 |
| 2026-06-11 | Twyman Roy Ervin · director | Award / grant | 16,568 | — | — | Form 4 |
| 2026-06-11 | June Carl Howard · director | Award / grant (derivative) | 38,889 | — | — | Form 4 |
| 2026-06-11 | Buetler Monika · director | Award / grant (derivative) | 41,667 | — | — | Form 4 |
| 2026-06-11 | Zuegel Martin · director, Interim CEO | Award / grant (derivative) | 77,778 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 46 reporting institutions held 25.1M shares ($68.6M, 24.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BVF INC/IL | 19,822,436 | $54.5M |
| 2 | WELLS FARGO & COMPANY/MN | 1,004,284 | $2.8M |
| 3 | MILLENNIUM MANAGEMENT LLC | 792,657 | $2.2M |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 624,367 | $1.7M |
| 5 | BlackRock, Inc. | 524,278 | $1.4M |
| 6 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 405,658 | $1.1M |
| 7 | DIMENSIONAL FUND ADVISORS LP | 390,165 | $1.1M |
| 8 | NORTHERN TRUST CORP | 278,513 | $766K |
| 9 | CITADEL ADVISORS LLC | 267,233 | $735K |
| 10 | MARSHALL WACE, LLP | 131,458 | $362K |
| 11 | Dauntless Investment Group, LLC | 107,489 | $296K |
| 12 | UBS Group AG | 101,629 | $279K |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 89,262 | $245K |
| 14 | MORGAN STANLEY | 89,253 | $245K |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 63,601 | $175K |